A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis
- PMID: 15604095
- DOI: 10.1093/carcin/bgi001
A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis
Abstract
Although mitochondrial deficiency in cancer has been described by Warburg, many years ago, the mechanisms underlying this impairment remain essentially unknown. Many types of cancer cells are concerned and, in particular, clear cell renal carcinoma (CCRC). In this cancer, the tumor suppressor gene, VHL (von Hippel-Lindau factor) is invalidated. Previous studies have shown that the transfection of the VHL gene in VHL-deficient cells originating from CCRCs could suppress their ability to form tumors when they were injected into nude mice. However, various additional genetic alterations are observed in such cancer cells. In order to investigate whether VHL invalidation was related to the mitochondrial impairment, we have studied the effects of wild-type VHL transfection into VHL-deficient 786-0 or RCC10 cells on their oxidative phosphorylation (OXPHOS) subunit contents and functions. We show that the presence of wild-type VHL protein (pVHL) increased mitochondrial DNA and respiratory chain protein contents and permitted the cells to rely on their mitochondrial ATP production to grow in the absence of glucose. In parallel to mtDNA increase, the presence of pVHL up regulated the mitochondrial transcription factor A, as shown by western blot analysis. In conclusion, in CCRCs, pVHL deficiency is one of the factors responsible for down-regulation of the biogenesis of OXPHOS complexes.
Similar articles
-
Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.Cancer Res. 2002 Jul 1;62(13):3803-11. Cancer Res. 2002. PMID: 12097293
-
Identification of novel VHL target genes and relationship to hypoxic response pathways.Oncogene. 2005 Jun 30;24(28):4549-58. doi: 10.1038/sj.onc.1208649. Oncogene. 2005. PMID: 15824735
-
The von Hippel-Lindau tumor suppressor gene and kidney cancer.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6290S-5S. doi: 10.1158/1078-0432.CCR-sup-040025. Clin Cancer Res. 2004. PMID: 15448019 Review.
-
In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations.Cancer Res. 2004 Dec 1;64(23):8595-603. doi: 10.1158/0008-5472.CAN-04-1430. Cancer Res. 2004. PMID: 15574766
-
The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.Am J Physiol Renal Physiol. 2004 Jul;287(1):F1-6. doi: 10.1152/ajprenal.00424.2003. Am J Physiol Renal Physiol. 2004. PMID: 15180922 Review.
Cited by
-
Alterations of oxidative phosphorylation in meningiomas and peripheral nerve sheath tumors.Neuro Oncol. 2016 Feb;18(2):184-94. doi: 10.1093/neuonc/nov105. Epub 2015 Jun 23. Neuro Oncol. 2016. PMID: 26106125 Free PMC article.
-
A message emerging from development: the repression of mitochondrial beta-F1-ATPase expression in cancer.J Bioenerg Biomembr. 2007 Jun;39(3):259-65. doi: 10.1007/s10863-007-9087-9. J Bioenerg Biomembr. 2007. PMID: 17712532 Review.
-
Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism.Br J Cancer. 2006 Jan 30;94(2):268-74. doi: 10.1038/sj.bjc.6602929. Br J Cancer. 2006. PMID: 16404428 Free PMC article.
-
Czech Footprints in the Bioenergetics Research.Physiol Res. 2024 May 31;73(Suppl 1):S23-S33. doi: 10.33549/physiolres.935395. Epub 2024 May 31. Physiol Res. 2024. PMID: 38836463 Free PMC article. Review.
-
Molecular analysis of tumor margins by MALDI mass spectrometry in renal carcinoma.J Proteome Res. 2010 May 7;9(5):2182-90. doi: 10.1021/pr900936z. J Proteome Res. 2010. PMID: 20141219 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources